Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study

The American Journal of Cardiology
T R PedersenIncremental Decrease in End Points Through Aggressive Lipid Lowering Study Group

Abstract

The Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) study is an investigator-initiated trial designed to determine whether additional clinical benefit might be gained through a strategy that decreases levels of low-density lipoprotein cholesterol levels better than those currently achieved with established statin therapy in patients who have coronary heart disease. IDEAL is a multicenter prospective, randomized, open-label, blinded, end point classification study. Patients who had myocardial infarction were randomized to prescription treatment with 80 mg/day of atorvastatin or 20 mg/day of simvastatin (the dose was increased to 40 mg/day at week 24 in those patients whose plasma total cholesterol remained >5.0 mmol/L, or 190 mg/dl, or whose low-density lipoprotein cholesterol remained >3.0 mmol/L, or 115 mg/dl). The primary clinical outcome variable is the time to initial occurrence of a major coronary event, which is defined as nonfatal acute myocardial infarction, coronary death, or resuscitated cardiac arrest. The study is designed to have a power of 90% to detect a relative decrease of 20% in the atorvastatin-group compared with the simvastatin-group in the number of major events caused by coron...Continue Reading

Citations

Feb 3, 2005·Current Atherosclerosis Reports·Allison M J Ross, Theodore G Ganiats
Apr 13, 2005·Atherosclerosis. Supplements·Lawrence A Leiter
Feb 25, 2006·The Canadian Journal of Cardiology·Lawrence A Leiter
Jul 12, 2007·The American Journal of Cardiology·Henry N GinsbergUNKNOWN ACCORD Study Group
May 20, 2008·Cardiovascular Therapeutics·Genovefa D KolovouDennis V Cokkinos
Dec 17, 2005·The American Journal of Medicine·Ian Graham
Feb 10, 2010·Journal of Internal Medicine·I HolmeUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group
Aug 19, 2015·Statistics in Medicine·Susanne StrohmaierOdd O Aalen
Jun 21, 2006·The American Journal of Cardiology·David D Waters
Mar 21, 2006·Atherosclerosis·S BöhlerUNKNOWN DETECT-Study Group
Jun 15, 2005·Expert Opinion on Pharmacotherapy·Kausik K Ray, Christopher P Cannon
Jun 17, 2005·Expert Opinion on Pharmacotherapy·Sander I van Leuven, John J P Kastelein
Jan 18, 2015·Heart·Robert M StoekenbroekUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group
Nov 16, 2005·Journal of the American College of Cardiology·Jennifer G RobinsonHelmut Schrott
Aug 12, 2016·International Journal of Cardiology·Prakash C DeedwaniaUNKNOWN TNT, CARDS and IDEAL Steering Committees and Investigators
Mar 27, 2009·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Ingar HolmeUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group
Apr 1, 2011·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Anders G OlssonUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group
Jun 1, 2014·The Cochrane Database of Systematic Reviews·Suetonia C PalmerGiovanni F M Strippoli
Feb 5, 2010·Circulation. Cardiovascular Genetics·Craig L HydeSara A Paciga
Sep 27, 2005·Expert Review of Cardiovascular Therapy·Harold BaysMichael Davidson
Nov 18, 2005·The Journal of Clinical Endocrinology and Metabolism·Henry N Ginsberg
Jan 23, 2009·Annals of Medicine·Ingar HolmeUNKNOWN Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.